Vident Advisory’s Apellis Pharmaceuticals APLS Stock Holding History

Vident Advisory’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,079	Closed	-$607K	–	1929
2026 Q1	$607K	Sell	15,079 -474	-3%	-$10.2K	0.01%	1146
2025 Q4	$391K	Sell	15,553 -19,828	-56%	-$465K	﹤0.01%	1279
2025 Q3	$801K	Buy	+35,381	New	+$825K	0.01%	935
2025 Q1	–	Sell	-14,564	Closed	-$465K	–	1555
2024 Q4	$465K	Buy	+14,564	New	+$438K	0.01%	991

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vident Advisory's APLS Position: Q2 2026 in Review

Vident Advisory sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 15,079 shares — an estimated $607K sold.

Vident Advisory first reported a position in APLS in Q4 2024 and held it in 4 quarters. The position peaked at $801K in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Vident Advisory reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Vident Advisory sold 15,079 Apellis Pharmaceuticals shares in Q2 2026, an estimated $607K.
Vident Advisory first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Vident Advisory's Apellis Pharmaceuticals position peaked at $801K in Q3 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.